Dehong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dehong Li has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Kaixu Li
School of Public Health, Gansu University of Chinese Medicine, Lanzhou, Gansu, 730000, People’s Republic of China
5 shared publicationsShujing Zhao
School of Public Health, Gansu University of Chinese Medicine, Lanzhou, Gansu, 730000, People’s Republic of China
5 shared publicationsHaiyu Wang
School of Public Health, Gansu University of Chinese Medicine, Lanzhou, Gansu, 730000, People’s Republic of China
4 shared publications- Yan Lu
Department of Clinical Laboratory, Gansu Provincial Hospital
4 shared publications Yumin Ding
School of Public Health, Gansu University of Chinese Medicine, Lanzhou, Gansu, 730000, People’s Republic of China
4 shared publicationsHeng Pan
School of Public Health, Gansu University of Chinese Medicine
3 shared publications
Latest Publications
- Open Access
- 12 June 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1849650
Optimizing COVID-19 vaccination strategies for high-risk populations: potential and challenges of combining heterologous boosting with respiratory mucosal delivery
Despite the decline of the global peak of COVID-19, SARS-CoV-2 continues to circulate, evolve, and undergo immune escape, posing persistent threats, particularly to older adults, individuals with comorbidities, and immunocompromised populations. Although existing vaccination strategies have substantially reduced the risks of severe disease, hospitalization, and death, their ability to block infection and transmission remains limited, and protection wanes over time. Current heterologous booster strategies still rely largely on combinations of different parenteral vaccine platforms. Although these regimens can enhance systemic humoral and cellular immunity, they are insufficient to robustly induce upper respiratory mucosal immunity, thereby limiting their role in early infection control and interruption of transmission. Because respiratory mucosal vaccines target the natural entry site of SARS-CoV-2, they have the potential to induce secretory IgA, tissue-resident memory immune cells, and local immune memory, offering distinct advantages in compensating for the shortcomings of conventional heterologous boosting. Combining heterologous boosting with respiratory mucosal delivery may further enhance the control of viral infection, early replication, and subsequent transmission while preserving systemic immunity, thereby providing more comprehensive immune protection for high-risk populations. However, this strategy still faces challenges related to mucosal barriers, delivery efficiency, adjuvant safety, manufacturing scale-up, and incomplete clinical evaluation frameworks. Future high-quality studies focusing on high-risk populations are needed to clarify its value in preventing infection, protecting against severe disease, and providing long-term protection.
- 12 June 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1849650
Open AccessOptimizing COVID-19 vaccination strategies for high-risk populations: potential and challenges of combining heterologous boosting with respiratory mucosal delivery
Despite the decline of the global peak of COVID-19, SARS-CoV-2 continues to circulate, evolve, and undergo immune escape, posing persistent threats, particularly to older adults, individuals with comorbidities, and immunocompromised populations. Although existing vaccination strategies have substantially reduced the risks of severe disease, hospitalization, and death, their ability to block infection and transmission remains limited, and protection wanes over time. Current heterologous booster strategies still rely largely on combinations of different parenteral vaccine platforms. Although these regimens can enhance systemic humoral and cellular immunity, they are insufficient to robustly induce upper respiratory mucosal immunity, thereby limiting their role in early infection control and interruption of transmission. Because respiratory mucosal vaccines target the natural entry site of SARS-CoV-2, they have the potential to induce secretory IgA, tissue-resident memory immune cells, and local immune memory, offering distinct advantages in compensating for the shortcomings of conventional heterologous boosting. Combining heterologous boosting with respiratory mucosal delivery may further enhance the control of viral infection, early replication, and subsequent transmission while preserving systemic immunity, thereby providing more comprehensive immune protection for high-risk populations. However, this strategy still faces challenges related to mucosal barriers, delivery efficiency, adjuvant safety, manufacturing scale-up, and incomplete clinical evaluation frameworks. Future high-quality studies focusing on high-risk populations are needed to clarify its value in preventing infection, protecting against severe disease, and providing long-term protection.
- Open Access
- 3 June 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1835847
COVID-19 vaccination in pregnancy: efficacy of second-generation vaccines, maternal-neonatal safety, and strategies to address vaccine hesitancy
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a profound impact on global public health. The Omicron variant, marked by high transmissibility and pronounced immune evasion capabilities, poses a particularly severe threat. Pregnant women undergo physiological immune modulation during pregnancy, which increases their susceptibility to severe disease following SARS-CoV-2 infection. This heightened risk is evidenced by elevated rates of intensive care unit (ICU) admission and increased maternal mortality. Additional pregnancy-related physiological changes—including heightened oxygen consumption and reduced respiratory reserve—further compromise respiratory function and worsen clinical outcomes in infected individuals. Although robust evidence confirms the efficacy and safety of COVID-19 vaccines, vaccine hesitancy remains prevalent among pregnant women due to concerns about potential adverse effects and fetal safety. This review evaluates current vaccination strategies for pregnant women using second-generation COVID-19 vaccines, with particular emphasis on maternal and neonatal health outcomes. It also analyzes barriers to vaccine uptake and underscores the need for further research to refine vaccination protocols, support equitable access, and ensure the safe and effective deployment of vaccines—ultimately mitigating the risks of SARS-CoV-2 infection during pregnancy.
- 3 June 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1835847
Open AccessCOVID-19 vaccination in pregnancy: efficacy of second-generation vaccines, maternal-neonatal safety, and strategies to address vaccine hesitancy
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a profound impact on global public health. The Omicron variant, marked by high transmissibility and pronounced immune evasion capabilities, poses a particularly severe threat. Pregnant women undergo physiological immune modulation during pregnancy, which increases their susceptibility to severe disease following SARS-CoV-2 infection. This heightened risk is evidenced by elevated rates of intensive care unit (ICU) admission and increased maternal mortality. Additional pregnancy-related physiological changes—including heightened oxygen consumption and reduced respiratory reserve—further compromise respiratory function and worsen clinical outcomes in infected individuals. Although robust evidence confirms the efficacy and safety of COVID-19 vaccines, vaccine hesitancy remains prevalent among pregnant women due to concerns about potential adverse effects and fetal safety. This review evaluates current vaccination strategies for pregnant women using second-generation COVID-19 vaccines, with particular emphasis on maternal and neonatal health outcomes. It also analyzes barriers to vaccine uptake and underscores the need for further research to refine vaccination protocols, support equitable access, and ensure the safe and effective deployment of vaccines—ultimately mitigating the risks of SARS-CoV-2 infection during pregnancy.
- Open Access
- 21 April 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1828887
Hybrid immunity strategies: heterologous vaccination combined with natural SARS-CoV-2 infection
The continuous evolution of SARS-CoV-2 poses a significant challenge to existing immune barriers, highlighting the limitations of single-modality immunization. Hybrid immunity, shaped by the combination of natural infection and vaccination, induces more potent, broad-spectrum, and durable protective immunity. This review proposes that heterologous vaccination – the sequential use of vaccines based on different technological platforms – can serve as an active public health strategy to simulate and optimize hybrid immunity. We systematically elaborate on the synergistic advantages of hybrid immunity at both the humoral and cellular levels, citing evidence from multiple clinical trials that for both convalescent individuals and infection-naïve populations, heterologous vaccination regimens outperform homologous regimens in enhancing the breadth of neutralizing antibodies, strengthening cross-protection, and establishing robust immune memory. By mimicking the antigenic distance effect, heterologous vaccination safely replicates the immunological benefits of natural infection without the associated risks, positioning it as a key strategic tool to counter persistent viral evolution and build a resilient population-wide immune barrier.
- 21 April 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1828887
Open AccessHybrid immunity strategies: heterologous vaccination combined with natural SARS-CoV-2 infection
The continuous evolution of SARS-CoV-2 poses a significant challenge to existing immune barriers, highlighting the limitations of single-modality immunization. Hybrid immunity, shaped by the combination of natural infection and vaccination, induces more potent, broad-spectrum, and durable protective immunity. This review proposes that heterologous vaccination – the sequential use of vaccines based on different technological platforms – can serve as an active public health strategy to simulate and optimize hybrid immunity. We systematically elaborate on the synergistic advantages of hybrid immunity at both the humoral and cellular levels, citing evidence from multiple clinical trials that for both convalescent individuals and infection-naïve populations, heterologous vaccination regimens outperform homologous regimens in enhancing the breadth of neutralizing antibodies, strengthening cross-protection, and establishing robust immune memory. By mimicking the antigenic distance effect, heterologous vaccination safely replicates the immunological benefits of natural infection without the associated risks, positioning it as a key strategic tool to counter persistent viral evolution and build a resilient population-wide immune barrier.
- Open Access
- 1 February 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-23
Proteomic Analysis of Cerebrospinal Fluid: Toward the Identification of Biomarkers for Early Central Nervous System Infection
Objective: Early diagnosis of central nervous system (CNS) infections remains challenging. The aim of this study was to explore and identify potential biomarkers of CNS infection by comparing cerebrospinal fluid (CSF) proteomic characteristics in patients with tuberculous meningitis (TBM), purulent meningitis (PM), and viral meningitis (VM), as well as in patients without CNS infections. Methods: We conducted the first systematic 4D-DIA comparative proteomic analysis of CSF across TBM (N=6), PM (N=6), VM (N=12), and controls (N=12) using pooled samples. Differential proteins were identified, subjected to GO and KEGG enrichment analyses, and used to construct protein-protein interaction networks for hub protein identification. Results: Proteomic analysis revealed significant differences in CSF protein expression profiles among three types of meningitis. In TBM patients, 53 specific proteins were identified, primarily involved in the complement and coagulation cascade as well as the COVID-19-related immune pathway. PPI network analysis highlighted FGA, FGB, C4BPA, and ADAMTS13 as hub proteins exhibiting notably significant expression levels in TBM patients. In PM patients, 9 proteins were identified, predominantly linked to phagosomes and B-cell receptor signaling, with COLEC11 and ESM1 showing significantly higher expression. In VM patients, 29 proteins were identified, mainly associated with complement and coagulation pathways, featuring higher levels of TMED7, MMP17, and CD81. Conclusion: This study delineated the CSF protein profiles in patients with TBM, PM, VM, and non-CNS infections. We identified several potential biomarkers, including FGA, FGB, C4BPA, ADAMTS13, COLEC11, ESM1, TMED7, MMP17, and CD81. Additionally, we proposed hypothetical molecular mechanisms that may offer valuable diagnostic and therapeutic insights for CNS infections. Nonetheless, given that this is a preliminary exploratory study, further validation through multicenter, large-sample cohort studies and functional experiments is necessary to substantiate the clinical relevance and utility of these biomarkers prior to any potential application in clinical practice.
- 1 February 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-23
Open AccessProteomic Analysis of Cerebrospinal Fluid: Toward the Identification of Biomarkers for Early Central Nervous System Infection
Objective: Early diagnosis of central nervous system (CNS) infections remains challenging. The aim of this study was to explore and identify potential biomarkers of CNS infection by comparing cerebrospinal fluid (CSF) proteomic characteristics in patients with tuberculous meningitis (TBM), purulent meningitis (PM), and viral meningitis (VM), as well as in patients without CNS infections. Methods: We conducted the first systematic 4D-DIA comparative proteomic analysis of CSF across TBM (N=6), PM (N=6), VM (N=12), and controls (N=12) using pooled samples. Differential proteins were identified, subjected to GO and KEGG enrichment analyses, and used to construct protein-protein interaction networks for hub protein identification. Results: Proteomic analysis revealed significant differences in CSF protein expression profiles among three types of meningitis. In TBM patients, 53 specific proteins were identified, primarily involved in the complement and coagulation cascade as well as the COVID-19-related immune pathway. PPI network analysis highlighted FGA, FGB, C4BPA, and ADAMTS13 as hub proteins exhibiting notably significant expression levels in TBM patients. In PM patients, 9 proteins were identified, predominantly linked to phagosomes and B-cell receptor signaling, with COLEC11 and ESM1 showing significantly higher expression. In VM patients, 29 proteins were identified, mainly associated with complement and coagulation pathways, featuring higher levels of TMED7, MMP17, and CD81. Conclusion: This study delineated the CSF protein profiles in patients with TBM, PM, VM, and non-CNS infections. We identified several potential biomarkers, including FGA, FGB, C4BPA, ADAMTS13, COLEC11, ESM1, TMED7, MMP17, and CD81. Additionally, we proposed hypothetical molecular mechanisms that may offer valuable diagnostic and therapeutic insights for CNS infections. Nonetheless, given that this is a preliminary exploratory study, further validation through multicenter, large-sample cohort studies and functional experiments is necessary to substantiate the clinical relevance and utility of these biomarkers prior to any potential application in clinical practice.
- 12 December 2025
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
The roles of macrophages in ankylosing spondylitis: from pathogenesis to therapeutic intervention target
Ankylosing spondylitis (AS) is a chronic autoimmune disease characterised by inflammation, bone destruction and pathological new bone formation in the spine and sacroiliac joints. Macrophages, as central innate immune cells, play a pivotal role in AS pathogenesis through dynamic polarisation into pro-inflammatory M1 and anti-inflammatory M2 phenotypes. M1 macrophages dominate early disease stages, producing cytokines such as TNF-α, IL-6 and IL-1β, activating Th1/Th17 responses, and driving tissue inflammation and osteoclast-mediated bone loss.M2 macrophages prevail in later stages, secreting IL-10 and TGF-β, promoting tissue repair, angiogenesis, and ectopic bone formation, contributing to spinal ankylosis. Their plasticity is regulated by cytokine and chemokine signalling, metabolic reprogramming, genetic variants and epigenetic modifications including RNA methylation, non-coding RNAs, and histone modifications. Targeting these pathways offers promising strategies to rebalance macrophage phenotypes, reduce inflammation and prevent structural damage.This review highlights macrophages as central drivers of AS progression and discusses emerging therapeutic approaches that exploit their regulatory mechanisms for precision treatment.
- 12 December 2025
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
The roles of macrophages in ankylosing spondylitis: from pathogenesis to therapeutic intervention target
Ankylosing spondylitis (AS) is a chronic autoimmune disease characterised by inflammation, bone destruction and pathological new bone formation in the spine and sacroiliac joints. Macrophages, as central innate immune cells, play a pivotal role in AS pathogenesis through dynamic polarisation into pro-inflammatory M1 and anti-inflammatory M2 phenotypes. M1 macrophages dominate early disease stages, producing cytokines such as TNF-α, IL-6 and IL-1β, activating Th1/Th17 responses, and driving tissue inflammation and osteoclast-mediated bone loss.M2 macrophages prevail in later stages, secreting IL-10 and TGF-β, promoting tissue repair, angiogenesis, and ectopic bone formation, contributing to spinal ankylosis. Their plasticity is regulated by cytokine and chemokine signalling, metabolic reprogramming, genetic variants and epigenetic modifications including RNA methylation, non-coding RNAs, and histone modifications. Targeting these pathways offers promising strategies to rebalance macrophage phenotypes, reduce inflammation and prevent structural damage.This review highlights macrophages as central drivers of AS progression and discusses emerging therapeutic approaches that exploit their regulatory mechanisms for precision treatment.
- Open Access
- 1 June 2025
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (6) , 3860-3873
Current and evolving practices of carbohydrate antigens in gastric cancer: a narrative review
Background and Objective: Carbohydrate antigens (CAs) are of great significance in various aspects of gastric cancer (GC). As new members of the family of CAs continue to be discovered, there is a growing focus on their role as therapeutic targets. The comprehensive review aims to provide an in-depth analysis of the current and evolving utilization of CAs in GC, offering valuable insights on the role of CAs as therapeutic targets or biomarkers for GC patients. Methods: A detailed narrative review of the most recent literature was conducted to assess the current use and advancements of CAs in GC. PubMed database was being examined and the last run was on 8 June 2024. Key Content and Findings: This article traces the discovery and biological properties of CAs and their role in GC clinical practice. CAs not only serve a crucial clinical function in the diagnosis, therapy monitoring, metastatic evaluation, and prognosis of GC, but they also improve biological performance when paired with other biomarkers. New CAs, like truncated O-glycans, gangliosides, globo-series glycan, and Lewis antigens, significantly influence GC progression, metastatic infiltration, and individual susceptibility. Moreover, these antigens exhibit unique potential in GC treatment, offering new approaches and insights for GC treatment. Conclusions: The use of CAs in GC diagnosis, prognosis, monitoring, and targeting therapy is beneficial. With the ongoing advancement of detection methodologies and technologies, challenges related to the sensitivity and specificity of CAs detection are anticipated to be progressively and effectively addressed. This will make its application in GC more widespread and effective.
- 1 June 2025
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (6) , 3860-3873
Open AccessCurrent and evolving practices of carbohydrate antigens in gastric cancer: a narrative review
Background and Objective: Carbohydrate antigens (CAs) are of great significance in various aspects of gastric cancer (GC). As new members of the family of CAs continue to be discovered, there is a growing focus on their role as therapeutic targets. The comprehensive review aims to provide an in-depth analysis of the current and evolving utilization of CAs in GC, offering valuable insights on the role of CAs as therapeutic targets or biomarkers for GC patients. Methods: A detailed narrative review of the most recent literature was conducted to assess the current use and advancements of CAs in GC. PubMed database was being examined and the last run was on 8 June 2024. Key Content and Findings: This article traces the discovery and biological properties of CAs and their role in GC clinical practice. CAs not only serve a crucial clinical function in the diagnosis, therapy monitoring, metastatic evaluation, and prognosis of GC, but they also improve biological performance when paired with other biomarkers. New CAs, like truncated O-glycans, gangliosides, globo-series glycan, and Lewis antigens, significantly influence GC progression, metastatic infiltration, and individual susceptibility. Moreover, these antigens exhibit unique potential in GC treatment, offering new approaches and insights for GC treatment. Conclusions: The use of CAs in GC diagnosis, prognosis, monitoring, and targeting therapy is beneficial. With the ongoing advancement of detection methodologies and technologies, challenges related to the sensitivity and specificity of CAs detection are anticipated to be progressively and effectively addressed. This will make its application in GC more widespread and effective.
- Open Access
- 29 January 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1510742
Application and progress of nomograms in gastric cancer
Gastric cancer, as one of the malignant tumors with a significant disease burden globally, emphasizes the importance of early diagnosis and personalized treatment for improving patient prognosis. In recent years, clinical prediction models (CPMs) have played a crucial role in predicting disease risks, assisting medical decision-making, and evaluating clinical prognosis and benefits as tools for risk–benefit assessment. Nomograms, as an important visualization form of clinical prediction models, have been increasingly applied in tumor-related research. Numerous studies have constructed multiple nomogram models by integrating clinical, pathological, laboratory, imaging data, and genetic characteristics, providing an accurate and effective tool for predicting the risk of gastric cancer, early diagnosis, treatment response assessment, and prognosis analysis. This article aims to review the current clinical applications and research progress of nomograms in gastric cancer, with the goal of providing robust references and theoretical support for clinical practice.
- 29 January 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1510742
Open AccessApplication and progress of nomograms in gastric cancer
Gastric cancer, as one of the malignant tumors with a significant disease burden globally, emphasizes the importance of early diagnosis and personalized treatment for improving patient prognosis. In recent years, clinical prediction models (CPMs) have played a crucial role in predicting disease risks, assisting medical decision-making, and evaluating clinical prognosis and benefits as tools for risk–benefit assessment. Nomograms, as an important visualization form of clinical prediction models, have been increasingly applied in tumor-related research. Numerous studies have constructed multiple nomogram models by integrating clinical, pathological, laboratory, imaging data, and genetic characteristics, providing an accurate and effective tool for predicting the risk of gastric cancer, early diagnosis, treatment response assessment, and prognosis analysis. This article aims to review the current clinical applications and research progress of nomograms in gastric cancer, with the goal of providing robust references and theoretical support for clinical practice.
- 22 January 2025
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 19 (3) , 91-99
Implications of Raftlin in different diseases: from molecular biology to diagnostic value
Raftlin (raft-linking) protein is an essential component of the lipid raft structure and plays a crucial role in B and T cell signaling pathways. It facilitates B cell receptor (BCR) signaling by promoting calcium mobilization and tyrosine phosphorylation in the cells while colocalizing with BCR on the cell membrane. Interestingly, Raftlin is internalized in lipopolysaccharide-stimulated T cells by colocalization with Toll-like receptor 4 (TLR4), wherein it exerts a similar role as in B cells. The protein also effectuates poly(I:C) internalization into TLR3-positive endosomes in dendritic and epithelial cells through clathrin binding, thereby affecting interferon-β production. In addition, Raftlin controls the vascular endothelial cells and participates in cell growth and proliferation. Recent studies have indicated Raftlin to be a novel biomarker for the diagnosis due to its upregulated expression in malignant diseases. In this integrated study, we present the biological functions of Raftlin and its expression to provide a theoretical basis for the prevention, diagnosis, and treatment of various diseases.
- 22 January 2025
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 19 (3) , 91-99
Implications of Raftlin in different diseases: from molecular biology to diagnostic value
Raftlin (raft-linking) protein is an essential component of the lipid raft structure and plays a crucial role in B and T cell signaling pathways. It facilitates B cell receptor (BCR) signaling by promoting calcium mobilization and tyrosine phosphorylation in the cells while colocalizing with BCR on the cell membrane. Interestingly, Raftlin is internalized in lipopolysaccharide-stimulated T cells by colocalization with Toll-like receptor 4 (TLR4), wherein it exerts a similar role as in B cells. The protein also effectuates poly(I:C) internalization into TLR3-positive endosomes in dendritic and epithelial cells through clathrin binding, thereby affecting interferon-β production. In addition, Raftlin controls the vascular endothelial cells and participates in cell growth and proliferation. Recent studies have indicated Raftlin to be a novel biomarker for the diagnosis due to its upregulated expression in malignant diseases. In this integrated study, we present the biological functions of Raftlin and its expression to provide a theoretical basis for the prevention, diagnosis, and treatment of various diseases.
- Open Access
- 29 November 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1463480
Establishment and validation of a nomogram model for early diagnosis of gastric cancer: a large-scale cohort study
Purpose: Identifying high-risk populations and diagnosing gastric cancer (GC) early remains challenging. This study aimed to establish and verify a nomogram model for the early diagnosis of GC based on conventional laboratory indicators.Methods: We performed a retrospective analysis of the clinical data of 2,770 individuals with first diagnosis of GC and 1,513 patients with benign gastric disease from January 2018 to December 2022. The cases were divided into the training set and validation set randomly, with a ratio of 7:3. Variable screening was performed by least absolute shrinkage and selection operator (LASSO) and logistic regression analysis. A nomogram was constructed in the training set to assist in the early diagnosis of GC.Results: There were 4283 patients included in the study, with 2998 patients assigned in the training set and 1285 patients in the validation set. Through LASSO regression and logistic regression analysis, independent variables associated with GC were identified, including CEA, CA199, LYM, HGB, MCH, MCHC, PLT, ALB, TG, HDL, and AFR. The nomogram model was constructed using the above 11 independent indicators. The AUC was 0.803 for the training set and 0.797 for the validation set, indicating that the model showed high clinical diagnostic efficacy. The calibration curves and decision curve analysis (DCA) of the nomogram presented good calibration and clinical application ability.Conclusion: Based on the analysis of large sample size, we constructed a nomogram model with 11 routine laboratory indicators, which showed good discrimination ability and calibration.
- 29 November 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1463480
Open AccessEstablishment and validation of a nomogram model for early diagnosis of gastric cancer: a large-scale cohort study
Purpose: Identifying high-risk populations and diagnosing gastric cancer (GC) early remains challenging. This study aimed to establish and verify a nomogram model for the early diagnosis of GC based on conventional laboratory indicators.Methods: We performed a retrospective analysis of the clinical data of 2,770 individuals with first diagnosis of GC and 1,513 patients with benign gastric disease from January 2018 to December 2022. The cases were divided into the training set and validation set randomly, with a ratio of 7:3. Variable screening was performed by least absolute shrinkage and selection operator (LASSO) and logistic regression analysis. A nomogram was constructed in the training set to assist in the early diagnosis of GC.Results: There were 4283 patients included in the study, with 2998 patients assigned in the training set and 1285 patients in the validation set. Through LASSO regression and logistic regression analysis, independent variables associated with GC were identified, including CEA, CA199, LYM, HGB, MCH, MCHC, PLT, ALB, TG, HDL, and AFR. The nomogram model was constructed using the above 11 independent indicators. The AUC was 0.803 for the training set and 0.797 for the validation set, indicating that the model showed high clinical diagnostic efficacy. The calibration curves and decision curve analysis (DCA) of the nomogram presented good calibration and clinical application ability.Conclusion: Based on the analysis of large sample size, we constructed a nomogram model with 11 routine laboratory indicators, which showed good discrimination ability and calibration.